Abstract: The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B 1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating preventing a condition or disorder responsive to the degradation of estrogen receptor protein (e.g., cancer).

Abstract: The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.

Abstract: The present disclosure relates to compounds of Formula (I), and the pharmaceutically A—(CH2)m—X—Y—Z—B1??I, acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer).

Abstract: Described herein are compounds of Formula I and conjugates of Formula I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).